Quick Answer
KYNTRA BIO, INC. reported Research And Development Expense of $23.52 million for the year ending 2025.
- KYNTRA BIO, INC. showed a decrease of -75.4% in Research And Development Expense from 2024 to 2025.
- This data is from KYNTRA BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $25.65 million | Q2 2014: $33.27 million | Q3 2014: $40.62 million | Q1 2015: $50.54 million | Q2 2015: $51.56 million | Q3 2015: $52.07 million | Q1 2016: $43.65 million | Q2 2016: $52.39 million | Q3 2016: $40.56 million | Q1 2017: $46.73 million | Q2 2017: $46.98 million | Q3 2017: $50.34 million | Q1 2018: $56.97 million | Q2 2018: $52.14 million | Q3 2018: $56.44 million | Q1 2019: $50.50 million | Q2 2019: $52.01 million | Q3 2019: $49.96 million | Q1 2020: $54.90 million | Q2 2020: $61.41 million | Q3 2020: $58.48 million | Q1 2021: $74.68 million | Q2 2021: $122.57 million | Q3 2021: $75.88 million | Q1 2022: $89.02 million | Q2 2022: $70.96 million | Q3 2022: $75.18 million | Q1 2023: $74.49 million | Q2 2023: $95.48 million | Q3 2023: $61.19 million | Q1 2024: $36.49 million | Q2 2024: $32.36 million | Q3 2024: $19.97 million | Q1 2025: $9.18 million | Q2 2025: $5.87 million | Q3 2025: $1.21 million.
- Over the full 13 years of available data (2013 to 2025), KYNTRA BIO, INC.'s Research And Development Expense has declined by 72.6%.
- Historical annual values: Fiscal year 2025: $23.52 million | Fiscal year 2024: $95.69 million | Fiscal year 2023: $266.47 million | Fiscal year 2022: $296.79 million | Fiscal year 2021: $387.04 million | Fiscal year 2020: $252.92 million | Fiscal year 2019: $209.27 million | Fiscal year 2018: $235.84 million | Fiscal year 2017: $196.52 million | Fiscal year 2016: $187.21 million | Fiscal year 2015: $214.09 million | Fiscal year 2014: $150.79 million | Fiscal year 2013: $85.71 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: